scholarly journals Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets – CORRIGENDUM

2015 ◽  
Vol 114 (1) ◽  
pp. 159-159 ◽  
Author(s):  
Tomoji Ono ◽  
Michiaki Murakoshi ◽  
Noriyuki Suzuki ◽  
Norio Iida ◽  
Motoyasu Ohdera ◽  
...  
Keyword(s):  
Abdominal Obesity ◽  
Visceral Fat ◽  
Japanese Men ◽  
Men And Women ◽  
Fat Accumulation ◽  
Visceral Fat Accumulation ◽  
Enteric Coated

scholarly journals Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets

2010 ◽  
Vol 104 (11) ◽  
pp. 1688-1695 ◽  
Author(s):  
Tomoji Ono ◽  
Michiaki Murakoshi ◽  
Noriyuki Suzuki ◽  
Norio Iida ◽  
Motoyasu Ohdera ◽  
...  
Keyword(s):  
Abdominal Obesity ◽  
Visceral Fat ◽  
Subcutaneous Fat ◽  
Japanese Men ◽  
Men And Women ◽  
Fat Accumulation ◽  
Visceral Fat Accumulation ◽  
The Metabolic Syndrome ◽  
Computed Tomography Images ◽  
Enteric Coated

Lactoferrin (LF), a multifunctional glycoprotein in mammalian milk, is reported to exert a modulatory effect on lipid metabolism. The aim of the present study was to elucidate whether enteric-coated LF (eLF) might improve visceral fat-type obesity, an underlying cause of the metabolic syndrome. Using a double-blind, placebo-controlled design, Japanese men and women (n26; aged 22–60 years) with abdominal obesity (BMI>25 kg/m2, and visceral fat area (VFA)>100 cm2) consumed eLF (300 mg/d as bovine LF) or placebo tablets for 8 weeks. Measurement of the total fat area, VFA and subcutaneous fat area from computed tomography images revealed a significant reduction in VFA ( − 14·6 cm2) in the eLF group, as compared with the placebo controls ( − 1·8 cm2;P = 0·009 by ANCOVA). Decreases in body weight, BMI and hip circumference in the eLF group ( − 1·5 kg, − 0·6 kg/m2, − 2·6 cm) were also found to be significantly greater than with the placebo (+1·0 kg, +0·3 kg/m2, − 0·2 cm;P = 0·032, 0·013, 0·041, respectively). There was also a tendency for a reduction in waist circumference in the eLF group ( − 4·4 cm) as compared with the placebo group ( − 0·9 cm;P = 0·073). No adverse effects of the eLF treatment were found with regard to blood lipid or biochemical parameters. From these results, eLF appears to be a promising agent for the control of visceral fat accumulation.

Fatty Liver Is a Better Marker of Muscle Insulin Resistance than Visceral Fat Accumulation in Nonobese Japanese Men

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1854-P
Author(s):  
SATOSHI KADOWAKI ◽  
YOSHIFUMI TAMURA ◽  
YUKI SOMEYA ◽  
KAGEUMI TAKENO ◽  
TAKASHI FUNAYAMA ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Fatty Liver ◽  
Visceral Fat ◽  
Japanese Men ◽  
Muscle Insulin Resistance ◽  
Fat Accumulation ◽  
Visceral Fat Accumulation

scholarly journals Visceral Fat Accumulation Is an Important Determinant of PAI-1 Levels in Young, Nonobese Men and Women

1998 ◽  
Vol 18 (11) ◽  
pp. 1716-1722 ◽  
Author(s):  
E. J. Giltay ◽  
J. M. H. Elbers ◽  
L. J. G. Gooren ◽  
J. J. Emeis ◽  
T. Kooistra ◽  
...  
Keyword(s):  
Visceral Fat ◽  
Important Determinant ◽  
Men And Women ◽  
Fat Accumulation ◽  
Visceral Fat Accumulation ◽  
Pai 1
Sign in / Sign up

Export Citation Format

Share Document